You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)SBC: LUNG THERAPEUTICS INC Topic: NHLBI
Abstract Systemic sclerosissclerodermaSScis a chronic connective tissue disease in which lung fibrosis is the most frequent cause of deathSSc and idiopathic pulmonary fibrosis are the two most common disease that falls under the interstitial lung diseasesILDa grouping of devastating diseases in which lung fibrosis leads to progressive shortness of breatha very poor quality of lifeand death within ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: INVENUX, LLC Topic: NCCAM
DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: CONVERGENT ENGINEERING, INC. Topic: NICHD
DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: New Horizons Diagnostics Topic: NCI
DESCRIPTION (provided by applicant): Prostate cancer is the second most common cancer in men, and the second leading cause of cancer death. However, when prostate cancer is diagnosed in its early stages, it can be effectively treated and cured. Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages. ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: ARCHIE MD INC. Topic: DHA17A002
Providing Army combat medics with meaningful experience in treatment of battlefield injuries is a particular challenge. Moulage has the potential to assist in acquiring what could otherwise be very hard-to-come-by preparatory experience for distressing real-life emergencies medics and soldiers may encounter in the field. However, current approaches to moulage are limited in their ability to reflec ...STTR Phase II 2018 Department of DefenseDefense Health Agency
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetesSBC: RIDGELINE THERAPEUTICS LLC Topic: NIDDK
ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degenerationSBC: RIDGELINE THERAPEUTICS LLC Topic: NIA
In the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)SBC: CENTERLINE BIOMEDICAL INC Topic: NHLBI
Project Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: South Plains Biotechnology, Inc Topic: 350
Project Summary Abstract Statement of the problemOnly three pharmacotherapeutic treatments for Alcohol Use DisorderAUDare FDA approved and none are widely usedandltof AUD patientsor show a strong effect to reduce riskyor dependence based drinking in the long termandltsee sustained decreased drinking outcomesUnfortunatelyapproximatelyof the population suffers from AUD and overof all medical morbidi ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIA
Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health